Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Expenses | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 |
| Operating Profit | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 |
| OPM % | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% |
| Other Income | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 |
| Interest | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 |
| Depreciation | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 |
| Profit before tax | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 |
| Tax % | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% |
| Net Profit | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| EPS in Rs | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 | 4,502 |
| Expenses | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,654 | 3,837 | 3,934 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 465 | 522 | 568 |
| OPM % | 8% | 9% | 7% | 9% | -2.4% | 8% | 3.0% | 11% | 12% | 13% |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 69 | 108 | 112 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 | 96 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 | 159 |
| Profit before tax | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 | 426 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% | 33% | |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 | 293 |
| EPS in Rs | 366.55 | 523.23 | 335.61 | 943.49 | -35.30 | 6.63 | -0.28 | 21.49 | 16.21 | 18.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 10% | 10% | 6% | 9% | ||
| Compounded Profit Growth | 16% | 16% | 29% | -7% | ||
| Stock Price CAGR | % | % | % | 86% | ||
| Return on Equity | % | 6% | 10% | 8% |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other Liabilities | 293 | 318 | 1,140 | 1,137 | 2,033 | 1,905 | 2,229 | 960 | 1,958 |
| Total Liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Fixed Assets | 444 | 501 | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,535 | 3,796 |
| Total Assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Cash from Investing Activity | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Cash from Financing Activity | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Free Cash Flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
| CFO/OP | 72% | 98% | 44% | 74% | -98% | 93% | 455% | 118% | 243% |
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 | 67 |
| Inventory Days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 | 110 |
| Days Payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash Conversion Cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 | 89 |
| Working Capital Days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
| ROCE % | 14% | 20% | -16% | 22% | 2% | 16% | 15% |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% |
| FIIs | 7.34% | 6.36% | 5.77% | 4.24% | 2.27% | 1.14% | 1.38% | 1.91% |
| DIIs | 7.53% | 6.99% | 7.39% | 8.85% | 9.28% | 14.41% | 14.36% | 13.44% |
| Public | 7.14% | 8.64% | 8.84% | 8.92% | 10.46% | 6.45% | 6.29% | 6.67% |
| Others | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% | 2.73% |
| No. of Shareholders | 57,531 | 68,410 | 69,366 | 69,424 | 75,365 | 76,869 | 72,589 | 70,289 |
Fundamentals
Market Cap₹ 12,899 Cr.
Current Price₹ 820
Stock P/E42.3
Book Value₹ 211
ROCE14.9 %
ROE8.45 %
Dividend Yield0.12 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)-7%
Consolidated figures.
Valuation
Market capRs 12,449 Cr
Enterprise valueRs 11,960 Cr
P/E (TTM)42.67x
Price to book4.09x
Price to sales2.77x
EV / EBITDA17.59x
EV / EBIT22.94x
EV / sales2.66x
Price to cash flow26.76x
Earnings yield2.34%
P/E, 3-year average21.42x
P/B, 3-year average2.38x
P/E, 5-year average21.42x
P/B, 5-year average2.38x
Profitability
Operating margin (excl. other income)11.28%
Operating margin (incl. other income)12.95%
EBITDA margin15.11%
Pre-tax margin9.46%
Net profit margin6.48%
Net margin, latest quarter8.57%
ROE18.00%
ROCE17.23%
ROA8.90%
ROE, 3-year average10.54%
ROCE, 3-year average11.45%
ROA, 3-year average3.93%
ROE, 5-year average2.67%
ROCE, 5-year average7.14%
ROA, 5-year average1.59%
ROIC (approx.)20.29%
Tax rate0.43%
Other income / net worth2.25%
Growth
Sales growth (latest year)-1.44%
Sales CAGR, 3 years3.90%
Sales CAGR, 5 years11.27%
Profit CAGR, 5 years50.60%
Sales growth QoQ0.76%
Profit growth QoQ18.20%
Sales growth YoY (latest quarter)13.93%
Profit growth YoY (latest quarter)57.55%
Per share
EPS (TTM)Rs 19.05
EPS (latest year)Rs 22.09
EPS (latest quarter)Rs 6.53
EPS, 3-year averageRs 9.48
EPS, 5-year averageRs 187.33
Book value per shareRs 199.02
Sales per shareRs 294.03
Cash flow per shareRs 30.39
Free cash flow per shareRs 62.57
Efficiency
Asset turnover1.01x
Fixed asset turnover2.95x
Inventory turnover3.96x
Inventory days92 days
Debtor days68 days
Debtors turnover5.35x
Creditor days87 days
Cash conversion cycle89 days
Working capital days66 days
Leverage
Total debtRs 88 Cr
Cash and bankRs 576 Cr
Net debtRs -488 Cr
Debt to equity0.03x
Net debt / EBITDA-0.72x
Interest coverage5.45x
Current ratio (filing 2026-03-31)3.25x
Quick ratio (filing 2026-03-31)2.56x
Trade payables (filing 2026-03-31)Rs 602 Cr
Owners' fund to total sources74.41%
Debt to assets2.15%
Cash flow
Cash from Operating Activity (latest year)Rs 465 Cr
Cash from Investing Activity (latest year)Rs -548 Cr
Cash from Financing Activity (latest year)Rs 73 Cr
Net Cash Flow (latest year)Rs -10 Cr
Free cash flow (latest year)Rs 958 Cr
FCFE (approx.: FCF + change in debt)Rs 481 Cr
Cash from ops / profit, 5 years5.25x
Sales to cash flow8.85x
Statement figures
Net sales (TTM)Rs 4,502 Cr
Net sales (latest year)Rs 4,118 Cr
Sales (latest quarter)Rs 1,167 Cr
Operating profit excl. other income (latest year)Rs 465 Cr
Operating profit (latest quarter)Rs 175 Cr
Other income (TTM)Rs 112 Cr
EBITDA (TTM)Rs 680 Cr
PBDT (TTM)Rs 584 Cr
Profit before tax (TTM)Rs 426 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 292 Cr
Net profit (latest year)Rs 338 Cr
Net profit (latest quarter)Rs 100 Cr
Depreciation (TTM)Rs 159 Cr
Depreciation (latest quarter)Rs 41 Cr
Interest (TTM)Rs 96 Cr
Cost of goods sold (latest year)Rs 2,696 Cr
Total expenditure (latest year)Rs 3,654 Cr
Total income (latest year)Rs 4,187 Cr
Share capitalRs 31 Cr
ReservesRs 3,016 Cr
Shareholders' fundsRs 3,047 Cr
Total assetsRs 4,095 Cr
Net blockRs 1,397 Cr
Capital work in progressRs 163 Cr
InvestmentsRs 0 Cr
ReceivablesRs 770 Cr
InventoryRs 681 Cr
Other liabilitiesRs 960 Cr
Shares outstanding (crore)15.31
Ownership
Promoter holding75.26% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 42.7 is at the 59th percentile of its own 2.2-year range
(median 37.4, low 19.8, high 139.5).
P/B 4.09 is at the 11th percentile (median 10.10).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | AKUMS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.6% | -2.8% | +2.2 pts |
| 1 month | +4.4% | -6.8% | +11.2 pts |
| 3 months | +29.7% | -7.6% | +37.3 pts |
| 6 months | +74.4% | +0.4% | +74.0 pts |
| 1 year | +77.3% | -9.9% | +87.2 pts |
| 2 years | -5.0% | -13.6% | +8.5 pts |
22 mutual fund schemes hold about ₹969 Cr.
Over three months 1 bought more and 21 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Franklin India Opportunities Fund | 2.02% | 197 | -9% |
| Franklin India Small Cap Fund | 1.11% | 164 | -11% |
| ICICI Pru Healthcare Fund- | 1.99% | 139 | -25% |
| Bandhan Small Cap Fund | 0.40% | 138 | -20% |
| Nippon India Pharma Fund | 1.11% | 105 | -17% |
| Franklin India Multi Cap Fund | 1.54% | 81 | -21% |
| ICICI Pru ELSS-Tax Saver Fund | 0.33% | 47 | -65% |
| Templeton India Value Fund | 1.82% | 36 | -23% |
| Altiva Equity Ex-Top 100 Long-Short Fund | 3.33% | 32 | -7% |
| JioBlackRock Flexi Cap Fund | 0.37% | 12 | -6% |
| Old Bridge Flexi Cap Fund | 2.19% | 9 | -25% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.28% | 7 | -10% |
| Samco Multi Cap Fund | 0.47% | 1 | -31% |
| Samco Small Cap Fund | 0.23% | 0 | +100% |
| Groww Nifty Total Market Index Fund | 0.01% | 0 | -9% |
| Bandhan BSE Healthcare Index Fund | 0.17% | 0 | -8% |
| Angel One Nifty Total Market Index Fund | 0.01% | 0 | -9% |
| Mirae Asset Nifty Total Market Index Fund | 0.01% | 0 | -9% |
| Bandhan Nifty Total Market Index Fund | 0.01% | 0 | -9% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% | 0 | -9% |
| Franklin India Multi-Factor Fund | 0.00% | 0 | -100% |
| ICICI Pru Aggressive Hybrid Fund(A | 0.00% | 0 | -100% |
Red flags
F-score 6 of 8| explain | Share dilution Share count up 10% in a year, 120% in three |
| look | Regulator order or action Regulator order or action 2026-07-04: Update on penalty imposed by the Deputy Commissioner of State Tax, Gujarat, on Maxcure Nutravedics Limited, wholly owned subsidiary of the C |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹1,167 Cr +14.0% vs Jun 2025.
Net profit ₹101 Cr +55.4%.
Against our estimate for Jun 2026: sales +1.5%, profit +43.9% in line. Our estimate for Sep 2026: sales Rs 1,138 Cr, profit Rs 73 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-07-03 | Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd (AKUMS) has a market capitalisation of Rs 12,899 Cr. at the 2026-10-01 close.
What is the P/E ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd trades at a P/E of 42.3 on trailing twelve-month profit, at the 2026-10-01 close.
What were Akums Drugs & Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Akums Drugs & Pharmaceuticals Ltd sales was Rs 1,167 Cr (+14.0% vs Jun 2025) and net profit was Rs 101 Cr.
What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd?
The 52-week high is Rs 838.80 and the 52-week low is Rs 409.30.